The liver hangs a hydroxyl on used estrogen; DIM and I3C tilt it toward the weaker branch, but a changed ratio is not less disease.
Full mechanism, in text
How it shifts estrogen breakdown
1. Used estrogen goes to the liver
Estrogen the body has already used is sent to the liver to be broken down, and the liver attaches a hydroxyl group at one of several carbon positions.Used first becomes estrone and is then sent to the liver. A group of cytochrome P450 enzymes attaches the hydroxyl group, and where that group lands decides the product.
2. Where the hydroxyl lands decides the product
On the 2-hydroxy path the product is weakly estrogenic and easily cleared; another path yields a product that is still estrogenic.CYP1A1 and CYP1A2 do 2-hydroxylation, which yields a weakly estrogenic product that the next enzyme clears easily. Another path yields 16α-hydroxyestrone, which is still estrogenic and binds the receptor more stably. A 4-hydroxy path can, in theory, become reactive fragments that stick to DNA.
3. DIM and I3C send more down the weaker branch
DIM and I3C can induce a liver enzyme that breaks down estrogen, sending more estrogen down the 2-hydroxy branch, whose products are weaker.The enzyme is called CYP1A1. Once it is induced, the metabolite ratio shifts toward the 2-hydroxy side. That step can be measured in people; the mechanism is real. Thomson 2017 confirmed the ratio moves in women taking tamoxifen. That is the scientific kernel of estrogen detox.
But in the same trial, women taking DIM had lower blood levels of tamoxifen's active metabolites, including endoxifen, than those on placebo, and whether that weakens the drug is not yet known. Anyone taking tamoxifen should ask their doctor before adding DIM.
4. A changed ratio is not less disease
A changed ratio on a lab sheet is not less disease: between the ratio and any disease outcome sit several unproven gates.Marketing calls this shift in the ratio detox, then jumps a step further to cancer prevention. Among the gates downstream: first, the ratio hypothesis itself is shaky. In large prospective cohorts its link to breast-cancer risk shows up in some and not in others; pooled, the signal is weak, and it is only an association. Second, changing a biomarker is not changing a disease. Third, how much a person absorbs is unstable, and within a single dose group people differ widely.
Whether that reduces breast cancer or improves periods or acne has mostly not been answered by any trial.